Abstract: SA-PO0773
Baseline Characteristics and Treatment Satisfaction of Patients (Pts) Enrolled in IgAN Bridge: Interim Results from a Home-Reported Outcomes (HROs) Study
Session Information
- Glomerular Research: Design, Registries, Surveys, and Epidemiology
November 08, 2025 | Location: Exhibit Hall, Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Glomerular Diseases
- 1402 Glomerular Diseases: Clinical, Outcomes, and Therapeutics
Authors
- Ndife, Briana C., Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, United States
- Canetta, Pietro A., Columbia University, New York, New York, United States
- Norouzi, Sayna, Loma Linda University, Loma Linda, California, United States
- Anwar, Hiba, Folia Health, Boston, Massachusetts, United States
- Stephens, Luke, Folia Health, Boston, Massachusetts, United States
- Khairnar, Rahul, Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, United States
- Zhang, Connie, Folia Health, Boston, Massachusetts, United States
- McStocker, Samantha, Folia Health, Boston, Massachusetts, United States
- Healey, Amanda, Folia Health, Boston, Massachusetts, United States
- Owashi, Jordan, Folia Health, Boston, Massachusetts, United States
- Villard, Sarah, Folia Health, Boston, Massachusetts, United States
- Trenz, Helen, Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, United States
- Alfano, Anne Marie, Bondville, Bondville, Vermont, United States
- Rice, Aran John, Boulder, Boulder, Colorado, United States
- Narayanan, Mohanram, Baylor Scott & White Health, Dallas, Texas, United States
Background
IgAN is the most common primary glomerulonephritis worldwide with heterogeneous clinical presentation and variable disease progression. There are limited data on how pts manage disease burden outside of clinical settings. HROs capture real-world insights into symptoms, disease burden, and impacts of treatment. This abstract presents a preliminary analysis of baseline characteristics, disease burden, and treatment patterns of pts enrolled in the ongoing IgAN Bridge Study.
Methods
This is a remote, prospective, 6-month observational study using a mobile app to collect HROs of pts with IgAN in the US. Enrollment began in March 2025; a wide-net enrollment and eligibility approach is used to recruit pts. Pts initially report their baseline health status, including treatment satisfaction, then select symptoms and treatments to track during the study. Monthly surveys assess health-related quality of life using Functional Assessment of Chronic Illness Therapy – Fatigue Scale (FACIT-Fatigue) and EQ-5D-5L scores. Baseline fatigue severity (BFS) is scored on a scale of 1 (least severe) to 5 (most severe).
Results
This preliminary analysis included 22 pts who selected 35 treatments and 38 symptoms to track. The most common treatments selected included sparsentan (18%), fish oil (18%), and empagliflozin (14%). The most common symptoms tracked included fatigue (77%), urine changes (50%), and difficulty sleeping (45%); 82% tracked blood pressure. Pts who completed baseline HROs (n=12) had a mean ± SD FACIT-Fatigue score of 32.5 ± 14.4 and EQ-5D-5L score of 0.8 ± 0.2. Symptom severity at baseline varied by treatment satisfaction: among pts who were “very satisfied,” 75% had a BFS score of 1–2, vs 25% with a BFS score of 3–5.
Conclusion
In this small initial sample of pts with IgAN, disease burden and treatment satisfaction varied at baseline. Pts with lower treatment satisfaction had greater symptom severity, and fatigue was the most frequently tracked symptom across satisfaction levels. This heterogeneity highlights the need to understand the diverse experiences and symptom burden of pts with IgAN.
Funding
- Commercial Support – Novartis Pharmaceutical Corporation